Caricamento...
Should minimal residual disease negativity be the end point of myeloma therapy?
Publisher's Note: This article has a companion Counterpoint by Sonneveld. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.
Salvato in:
| Pubblicato in: | Blood Adv |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society of Hematology
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5728451/ https://ncbi.nlm.nih.gov/pubmed/29296970 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016000117 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|